SS
GRCE

SBI Securities’s Grace Therapeutics GRCE Stock Holding History

SBI Securities’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175 Buy
77
+7
+10% +$19 ﹤0.01% 3362
2026
Q1 		$324 Sell
70
-31
-31% -$122 ﹤0.01% 3050
2025
Q4 		$349 Hold
101
– – ﹤0.01% 3007
2025
Q3 		$301 Hold
101
– – ﹤0.01% 3187
2025
Q2 		$300 Hold
101
– – ﹤0.01% 3179
2025
Q1 		$230 Buy
101
+100
+10,000% +$315 ﹤0.01% 3172
2024
Q4 		$4 Buy
+1
New +$3 ﹤0.01% 4025

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SBI Securities's GRCE Position: Q2 2026 in Review

SBI Securities increased its Grace Therapeutics (GRCE) stake by 10% in Q2 2026, buying an estimated $19 and bringing the position to 77 shares worth $175. The position accounts for ﹤0.01% of the portfolio, ranked #3362.

SBI Securities first reported a position in GRCE in Q4 2024 and has held it in 7 quarters since. The position peaked at $349 in Q4 2025. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • SBI Securities held 77 shares of Grace Therapeutics worth $175 as of Q2 2026.
  • SBI Securities bought 7 Grace Therapeutics shares in Q2 2026, an estimated $19.
  • Grace Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3362 holding.
  • SBI Securities first reported a position in Grace Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Grace Therapeutics position peaked at $349 in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.